New ワクチン 工場／植物 in Senegal gets 75 million euros from EIB
DAKAR, June 2 (Reuters) - The European 投資 Bank (EIB) committed 75 million euros ($80 million) on Thursday to 財政／金融 construction of a new 施設 in Senegal that will produce COVID-19 and other ワクチンs for use across Africa.
The 工場／植物, run by the Paris-based Institut Pasteur, is ーするつもりであるd to help Africa 減ずる its dependence on ワクチン 輸入するs, which 現在／一般に account for 99% of the continent's needs. It will produce ワクチンs against COVID-19, yellow fever and other endemic 病気s.
The EIB and the European Union had already 寄付するd 5 million euros in 2021 for 実現可能 熟考する／考慮するs and 事業／計画（する） 準備 for the 工場／植物.
Institut Pasteur hopes the 施設 will begin producing ワクチンs before the end of the year. At 十分な capacity, it should produce up to 300 million ワクチン doses per year, the EIB said in a 声明 発表するing the new 財政／金融ing.
Africa's 依存 on outside 製造業の 延期するd the rollout of COVID ワクチンs last year. Doses have since arrived in 軍隊, but inoculation 率s remain low in many countries 予定 to logistical challenges and ワクチン hesitancy.
"It is 必須の to create decentralised ワクチン 製造業の capacity to 演説（する）／住所 this 不均衡 and 最終的に build a safer and healthier world," said Amadou Alpha Sall, Institut Pasteur's director in Senegal.
There have been several 率先s during the pandemic to 上げる ワクチン 製造業の in Africa, but some have struggled.
South Africa's Aspen Pharmacare said last month it might 削除する its capacity to 一括 and sell the COVID ワクチン made by Johnson & Johnson after receiving no orders. ($1 = 0.9348 euro) (報告（する）／憶測ing by Aaron Ross; editing by Jonathan Oatis)
